- Home
- HFBL vs APLT Comparison
HFBL vs APLT Comparison
Compare HFBL & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HFBL | APLT |
|---|---|---|
| Founded | 1924 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.6M | 38.1M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | HFBL | APLT |
|---|---|---|
| Price | $15.99 | $0.22 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $1.25 |
| AVG Volume (30 Days) | 2.9K | ★ 26.6M |
| Earning Date | 10-23-2025 | 11-13-2025 |
| Dividend Yield | ★ 3.38% | N/A |
| EPS Growth | ★ 35.20 | N/A |
| EPS | ★ 1.47 | N/A |
| Revenue | ★ $21,720,000.00 | $1,000,000.00 |
| Revenue This Year | N/A | $124.18 |
| Revenue Next Year | N/A | $66.67 |
| P/E Ratio | $10.89 | ★ N/A |
| Revenue Growth | ★ 10.10 | N/A |
| 52 Week Low | $12.30 | $0.20 |
| 52 Week High | $16.95 | $1.50 |
Technical Indicators
Market Signals| Indicator | HFBL | APLT |
|---|---|---|
| Relative Strength Index (RSI) | 59.69 | 28.07 |
| Support Level | $15.61 | $0.20 |
| Resistance Level | $16.10 | $0.24 |
| Average True Range (ATR) | 0.14 | 0.04 |
| MACD | -0.04 | 0.01 |
| Stochastic Oscillator | 43.53 | 5.61 |
Price Performance
Historical ComparisonAbout HFBL Home Federal Bancorp Inc. of Louisiana
Home Federal Bancorp Inc of louisiana operates as a bank holding company. It is a federally chartered stock savings bank, which provides financial services to individuals, corporate entities, and other organizations. Its core activities consist of attracting deposits from the general public and using those funds to originate loans to the residential, commercial and multi-family segments. The company also invests securities held-to-maturity and securities available for sale.
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.